To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Cambridge drugmaker plans to ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min While Biogen's new CEO says he ...

BOSTON (AP) — Biogen has agreed to pay $900 million to resolve allegations that it violated federal law by paying kickbacks to doctors to persuade them to prescribe its multiple sclerosis drugs, ...

A game of real estate musical chairs is underway in Kendall Square as Biogen hands the deed from one of its East Coast sites to office aficionado Boston Properties (BXP). Wednesday, the Big Biotech ...

Biogen Inc. said it will continue development of its experimental Alzheimer’s drug after getting promising though not ...

Biogen (NASDAQ: BIIB) has had a rocky few years. Its multiple sclerosis franchise has been bleeding market share to generics ...

As Biogen's sales tumble in the wake of its troubled Aduhelm launch, the company is looking to exit some office space in the Boston area. Biogen has listed more than 183,500 square feet of office ...

Naomi Fried, Boston Children’s Hospital’s Chief Innovation Officer, is leaving the hospital to become Vice President of Medical Information, Innovation, and External Partnerships at Biogen Idec, ...

Chris Viehbacher defended the $26,500 annual price for Leqembi, days after an advisory panel recommended it for expanded approval Three days after an influential advisory panel recommended expanded US ...